Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 7/20 | 0.37 |
| ▸ | JAK1 | P23458 | 7/20 | 0.37 |
| ▸ | TYK2 | P29597 | 7/20 | 0.37 |
| ▸ | JAK3 | P52333 | 7/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | ULK1 | O75385 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082702 | 0.95 | JAK2 (0.40) | NPC1RAB9AMAPTJAK2JAK1 | |
| Trifluoroacetic Acid SCHEMBL4358380 | 0.90 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ALK | |
| Trifluoroacetic Acid SCHEMBL4356679 | 0.86 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL1072627 | 0.86 | JAK2 (0.44) | JAK2JAK1TYK2JAK3ALK | |
| Trifluoroacetic Acid SCHEMBL4365885 | 0.84 | JAK2 (0.40) | NPC1RAB9AJAK2JAK1TYK2 | |
| Trifluoroacetic Acid SCHEMBL4354803 | 0.84 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ALK | |
| Trifluoroacetic Acid SCHEMBL4361936 | 0.83 | JAK2 (0.42) | JAK2JAK1TYK2JAK3ALK | |
| Trifluoroacetic Acid SCHEMBL4361193 | 0.83 | JAK2 (0.39) | MAPTJAK2JAK1TYK2JAK3 | |
| Trifluoroacetic Acid SCHEMBL4357970 | 0.82 | NPC1 (0.38) | NPC1RAB9AMAPTJAK2JAK1 | |
| Trifluoroacetic Acid SCHEMBL1074800 | 0.82 | JAK2 (0.53) | JAK2JAK1TYK2JAK3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | NPC1 2849/4885RAB9A 1998/4885MAPT 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.